Targeting therapeutic approaches and highlighting the potential role of nanotechnology in atopic dermatitis

被引:17
作者
Singh, Sukhbir [1 ]
Behl, Tapan [1 ]
Sharma, Neelam [1 ]
Zahoor, Ishrat [1 ]
Chigurupati, Sridevi [2 ]
Yadav, Shivam [3 ]
Rachamalla, Mahesh [4 ]
Sehgal, Aayush [1 ]
Naved, Tanveer [5 ]
Pritima [1 ]
Arora, Sandeep [1 ]
Bhatia, Saurabh [6 ,7 ]
Al-Harrasi, Ahmed [6 ]
Mohan, Syam [8 ]
Aleya, Lotfi [7 ]
Bungau, Simona [9 ]
机构
[1] Chitkara Univ, Chitkara Coll Pharm, Rajpura, Punjab, India
[2] Qassim Univ, Dept Med Chem & Pharmacognosy, Buraydah, Saudi Arabia
[3] Yashraj Inst Pharm, Noida, Uttar Pradesh, India
[4] Univ Saskatchewan, Dept Biol, 112 Sci Pl, Saskatoon, SK, Canada
[5] Amity Univ, Amity Inst Pharm, Noida, Uttar Pradesh, India
[6] Univ Nizwa, Nat & Med Sci Res Ctr, Nizwa, Oman
[7] Univ Petr & Energy Studies, Sch Hlth Sci, Dehra Dun, Uttarakhand, India
[8] Jazan Univ, Substance Abuse & Toxicol Res Ctr, Jazan, Saudi Arabia
[9] Univ Oradea, Fac Med & Pharm, Dept Pharm, Oradea, Romania
关键词
Atopic dermatitis; Food allergy; Filaggrin; Topical corticosteroids; Emollients; Topical calcineurin inhibitors; Wet wrap therapy; SOLID LIPID NANOPARTICLES; INFANT NUTRITIONAL INTERVENTION; STAPHYLOCOCCUS-AUREUS COLONIZATION; TOPICAL CALCINEURIN INHIBITORS; OF-FUNCTION MUTATIONS; WET-WRAP DRESSINGS; SKIN BARRIER; EPIDERMAL BARRIER; FOOD ALLERGY; DOUBLE-BLIND;
D O I
10.1007/s11356-021-18429-8
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Atopic dermatitis is a chronic as well as widespread skin disease which has significant influence on the life attributes of affected people and their families. Systemic immunosuppressive drugs can be utilised for effective care of disease, although they are often prescribed for rigorous disruption or disease that is complicated to manage. Therefore, topical applications of corticosteroids are considered the primary pharmacologic therapies for atopic dermatitis, and research recommends that these medications might be helpful in preventing disease flare-ups. However, topical medicine administration to deeper layers of skin is challenging because of the skin anatomic barrier that restricts deeper drug permeation, and also due to barrier function abnormalities in atopic dermatitis skin, which might result in systemic drug absorption, provoking systemic consequences. Hence, effective management of atopic dermatitis needs new, effective, safe and targeted treatments. Therefore, nanotechnology-based topical therapeutics have attracted much interest nowadays because of their tendency to increase drug diffusion and bioavailability along with enormous drug targeting potential to affected cells, and, thereby, reducing the adverse effects of medications. In this review, we mention different symptoms of atopic dermatitis, and provide an overview of the different triggering factors causing atopic dermatitis, with emphasis on its epidemiology, pathophysiology, clinical features and diagnostic, and preventive measures. This review discusses existing therapeutics for treating atopic dermatitis, and the newer approaches as well as the current classical pharmacotherapy of atopic dermatitis against new nanoparticle skin delivery systems. This review has also briefly summarised the recent patents and clinical status of therapeutic modalities for atopic dermatitis.
引用
收藏
页码:32605 / 32630
页数:26
相关论文
共 229 条
[1]   The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies [J].
Abuabara, K. ;
Yu, A. M. ;
Okhovat, J. -P. ;
Allen, I. E. ;
Langan, S. M. .
ALLERGY, 2018, 73 (03) :696-704
[2]   Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook [J].
Ahluwalia, Jusleen ;
Udkoff, Jeremy ;
Waldman, Andrea ;
Borok, Jenna ;
Eichenfield, Lawrence F. .
DRUGS, 2017, 77 (13) :1389-1397
[3]   Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report [J].
Akdis, Cezmi A. ;
Akdis, Mubeccel ;
Bieber, Thomas ;
Bindslev-Jensen, Carsten ;
Boguniewicz, Mark ;
Eigenmann, Philippe ;
Hamid, Qutayba ;
Kapp, Alexander ;
Leung, Donald Y. M. ;
Lipozencic, Jasna K. ;
Luger, Thomas A. ;
Muraro, Antonella ;
Novak, Natalija ;
Platts-Mills, Thomas A. E. ;
Rosenwasser, Lanny ;
Scheynius, Annika ;
Simons, F. Estelle R. ;
Spergel, Jonathan ;
Turjanmaa, Kristiina ;
Wahn, Ulrich ;
Weidinger, Stefan ;
Werfel, Thomas ;
Zuberbier, Torsten .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (01) :152-169
[4]   Partially Hydrolyzed 100% Whey Protein Infant Formula and Reduced Risk of Atopic Dermatitis: A Meta-analysis [J].
Alexander, Dominik D. ;
Cabana, Michael D. .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2010, 50 (04) :422-430
[5]   Atopic dermatitis and alternative management strategies [J].
Anderson, P. Chris ;
Dinulos, James G. .
CURRENT OPINION IN PEDIATRICS, 2009, 21 (01) :131-138
[7]   Management of Difficult-to-Treat Atopic Dermatitis [J].
Arkwright, Peter D. ;
Motala, Cassim ;
Subramanian, Hamsa ;
Spergel, Jonathan ;
Schneider, Lynda C. ;
Wollenberg, Andreas .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2013, 1 (02) :142-151
[8]  
Aruna Railkar, 2020, Patent No. [CN110809471, 110809471]
[9]  
Aruna Railkar, 2020, Patent No. [EP3615032, 3615032]
[10]   Topical pimecrolimus for eczema [J].
Ashcroft, D. M. ;
L-C, Chen ;
Garside, R. ;
Stein, K. ;
Williams, H. C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (04)